Semaglutide vs bariatric surgery: how do the two approaches stack up?

How much weight do people actually lose with each approach?

The STEP 1 trial, published in the New England Journal of Medicine, found that adults taking semaglutide 2.4mg lost around 15% of their body weight on average over 68 weeks alongside lifestyle changes. That is a meaningful result for a medicine taken at home, with no anaesthetic and no recovery time.

Bariatric surgery typically delivers larger losses, gastric bypass produces average reductions of around 25–30% of total body weight over one to two years, and sleeve gastrectomy around 20–25%, though figures vary considerably by study, patient mix and follow-up length. Surgery also tends to produce more durable results without ongoing medication, particularly for those with type 2 diabetes, where remission rates are high.

The newer semaglutide dose comparisons show the gap narrowing: the recently approved 7.2mg Wegovy pen (MHRA-approved April 2026) delivered around 20.7% average weight loss in trials, bringing it closer to sleeve gastrectomy territory. The honest answer is that surgery still leads on magnitude for most people, but semaglutide has closed the distance considerably, and if you want to understand how GLP-1 receptor agonists relate to semaglutide specifically, that distinction matters when deciding which comparison is most relevant to you.

What are the risks on each side of the comparison?

Bariatric surgery is a major operation under general anaesthetic. Serious complications include anastomotic leaks, nutritional deficiencies requiring lifelong supplementation, and a small but real perioperative mortality risk (approximately 0.1–0.3% for elective procedures in the UK). Many people also experience dumping syndrome, reflux, or psychological challenges around eating after surgery. These are not reasons to avoid surgery, they are reasons to weigh it carefully.

Semaglutide's side-effect profile is led by gastrointestinal symptoms: nausea, loose stools, constipation and reflux are common, especially in the first weeks of treatment or after a dose step. Most settle with time. The NHS semaglutide medicines page lists the full profile clearly. In January 2026 the MHRA issued a Drug Safety Update for GLP-1 medicines highlighting acute pancreatitis as an infrequent but serious risk; severe, persistent abdominal pain radiating to the back warrants urgent medical attention. Semaglutide is not recommended during pregnancy, while breastfeeding, or when trying to conceive, and it is not licensed for use in under-18s.

One practical difference worth naming: stopping semaglutide typically results in weight regain, because the medicine manages rather than resolves the underlying biology. Surgery alters anatomy permanently, which is a drawback if complications arise and a potential advantage for long-term weight maintenance.

Who tends to be offered surgery versus a GLP-1 medicine on the NHS?

NICE recommends semaglutide (Wegovy) for weight management under TA875 within specialist weight management services, for adults with a BMI of 35 or above and at least one weight-related condition, for a maximum of two years. NHS waiting lists for both pathways can be long.

Bariatric surgery on the NHS is generally reserved for adults with a BMI of 40 or above (or 35 with a significant comorbidity), who have already tried all appropriate non-surgical options and are fit for general anaesthesia. In practice, surgical referral through the NHS is difficult to access and waiting times in many areas run to several years.

For those who do not meet NHS criteria, cannot wait, or prefer to explore a medicine-based route, private treatment through a regulated online pharmacy is one option, subject to a full clinical consultation. Our clinical team can discuss whether semaglutide is clinically appropriate for your situation. You can explore Wegovy pricing and what it includes before starting.

How do the two options compare at a glance?

Which approach is right for you depends on your BMI, comorbidities, surgical fitness, personal preferences and what you are prepared to commit to long-term. That is not a table's job to decide. It is a clinical conversation, the kind our prescribers have regularly, and the kind a bariatric surgical team would have with you too.

If semaglutide is the route you want to explore first, our weight-loss treatment overview covers the full picture. You can also read about how semaglutide and Ozempic relate to each other if that question has come up for you, or look at how liraglutide sits alongside semaglutide if you are weighing earlier-generation options. Check your eligibility by starting a free consultation, a GPhC-registered prescriber will review your answers the same day.